Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 9/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | HHAT | Q5VTY9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3609875 | 0.90 | ACE (0.41) | F11XIAPACEMTNR1B | |
| SCHEMBL3610934 | 0.90 | GHSR (0.43) | F11XIAPACE | |
| SCHEMBL3608895 | 0.88 | XIAP (0.40) | F11XIAPACEPPARGPPARD | |
| SCHEMBL3612584 | 0.87 | XIAP (0.42) | F11XIAPACEPPARGPPARD | |
| SCHEMBL3608946 | 0.83 | F11 (0.38) | F11XIAP | |
| SCHEMBL3608334 | 0.79 | XIAP (0.41) | F11XIAPACEPPARGPPARD | |
| SCHEMBL3609009 | 0.77 | XIAP (0.42) | F11XIAPACE | |
| SCHEMBL3598924 | 0.75 | XIAP (0.40) | F11XIAPPPARGPPARDPPARA | |
| SCHEMBL3602362 | 0.74 | XIAP (0.33) | XIAP | |
| SCHEMBL3607627 | 0.74 | ACE (0.47) | XIAPACEMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | F11 4805/4885XIAP 934/4885ACE 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.